RPG Life Sciences Limited’s stock rallied 9.36% to ₹2,279.20 on the NSE as of 9:57 AM, driven by its strong Q3 FY25 results. The company reported a 31.99% year-on-year increase in net profit to ₹34.93 crore, reflecting improved margins and effective cost management. Revenue from operations stood at ₹172.71 crore, showcasing a 12.37% growth compared to ₹153.70 crore in Q3 FY24, indicating consistent demand for its pharmaceutical products.
The company achieved an EBITDA margin of 28.6%, up from 24.7% a year ago, demonstrating operational efficiency. Earnings Per Share (EPS) saw remarkable growth, reaching ₹21.12, a 32% increase compared to ₹16.00 in Q3 FY24. Sequentially, revenue and profit before tax (PBT) grew by 0.29% and 10.63%, respectively, indicating steady progress despite challenges.
RPG Life Sciences faced a disruption due to a fire incident affecting one of its manufacturing blocks. However, the company showcased resilience in managing operations, with insurance claims expected to be realized in subsequent quarters. Strong performance across key product segments also contributed to the quarterly growth, bolstering investor confidence.
The company’s ability to maintain revenue growth stability and achieve profitability improvements positions it well for continued growth. Its focus on operational efficiencies and resilience in navigating disruptions has instilled optimism among market participants.
Disclaimer:
The above article is for informational purposes only. Please consult your financial advisor before making any investment decisions. Business Upturn does not recommend buying or selling any stock.